Get started

Financials · OKUR

OnKure Therapeutics Inc. (OKUR) financials

For the twelve months ended Sep 30, 2026, OnKure Therapeutics Inc. reported $4.14M of revenue and -$61.85M of net income.

Revenue, TTM
$4.14M
Net income, TTM
-$61.85M
Net margin
-1492.6%
Free cash flow, TTM
-$47.94M
EPS, diluted, TTM
-$2.76
Cash
$151.44M
P/S
33.13
Market cap
$137.3M
Annual revenue$3.44M
FY2023FY2025
Annual net income-$59.52M
FY2020FY2025
Annual free cash flow-$51.87M
FY2020FY2025

OKUR revenue and earnings growth

OKUR revenueQ3 2026$1.50M

Quarter YoY
+87.2%
QoQ
-3.1%

OKUR revenue was $1.50M in fiscal Q3 2026 (ended Sep 30, 2026), up 87.2% from a year earlier and down 3.1% from the prior quarter. For the full fiscal 2025 it was $3.44M, compared with $0 in fiscal 2024.

OKUR net incomeQ3 2026-$17.85M

OKUR net income was -$17.85M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$14.70M a year earlier. For the full fiscal 2025 it was -$59.52M, compared with -$52.67M in fiscal 2024.

OKUR EPSQ3 2026-$0.36

OKUR diluted EPS was -$0.36 in fiscal Q3 2026 (ended Sep 30, 2026). For the full fiscal 2025 it was -$4.40.

OKUR free cash flowQ3 2026-$13.11M

OKUR free cash flow was -$13.11M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$13.04M a year earlier. For the full fiscal 2025 it was -$51.87M, compared with -$51.17M in fiscal 2024.

Export CSV

Income statement

Income statement
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
Revenue$3.44M$0$1.62M---
Research and development$48.26M$43.80M$32.12M$37.70M$28.17M$15.94M
Selling, general and admin$14.69M$10.59M$4.82M$16.14M$11.65M$3.61M
Operating income-$62.95M-$54.39M-$36.93M-$53.85M-$39.82M-$19.55M
Pre-tax income---$77.39M-$51.95M-$39.77M-$19.46M
Income tax$0$0$0$0$0$0
Net income-$59.52M-$52.67M-$35.31M-$51.95M-$39.77M-$19.46M
EPS, basic-$4.40-$15.28-$124.41-$21.20-$21.90-$96.00
EPS, diluted-$4.40-$15.28-$124.41-$21.20-$21.90-$96.00
Diluted shares13.5M3.4M283,8172.4M1.8M202,819.8

Balance sheet

Balance sheet
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
Cash and equivalents$59.05M$110.76M$29.88M$11.54M$124.66M$53.61M
Short-term investments--$75.33M$81.25M$23.01M-
Current assets$60.84M$113.00M$33.77M$106.35M$153.73M$55.02M
Total assets$62.12M$114.91M$35.73M$108.18M$154.02M$55.22M
Current liabilities$5.92M$10.53M$7.29M$7.12M$6.20M$4.58M
Total liabilities$5.93M$11.08M$7.75M$8.21M$6.81M$4.62M
Shareholders' equity$56.18M$103.83M-$101.84M-$54.42M$147.21M-$42.12M

Cash flow

Cash flow
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
Operating cash flow-$51.83M-$51.12M-$34.55M-$47.36M-$37.98M-$18.54M
Capital expenditures$46.0K$52.0K$246.0K$346.0K$198.0K$24.0K
Free cash flow-$51.87M-$51.17M-$34.79M-$47.71M-$38.18M-$18.56M
Investing cash flow-$46.0K$15.87M-$246.0K-$57.84M-$23.38M$7.38M
Financing cash flow$163.0K$116.13M$53.13M$471.0K$132.41M$47.27M
Share repurchases--$4.40M---
Stock-based compensation$11.63M$4.53M$199.0K$4.32M$3.89M$393.0K
Depreciation and amortization$447.0K$459.0K$417.0K$88.0K$50.0K$37.0K

Key ratios

Key ratios
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
Revenue growth, YoY--100.0%----
Operating margin-1829.4%--2275.7%---
Net margin-1729.6%--2175.7%---
Free cash flow margin-1507.5%--2143.7%---
Return on equity-105.9%-50.7%---27.0%-
Return on assets-95.8%-45.8%-98.8%-48.0%-25.8%-35.2%
Current ratio10.2810.734.6414.9324.7912.01

Source: XBRL data OnKure Therapeutics Inc. files with the SEC, latest filing dated Nov 4, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.

* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.

Per-share figures and share counts are restated for stock splits the filings show: 1-for-10, first reported Nov 7, 2024.

EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.

OKUR peers

CompanyRevenueGrowthNet incomeNet marginMarket cap
OKUR$4.14M--$61.85M-1492.6%$137.3M
LLY$86.46B+45.5%$27.58B31.9%$1.35T
JNJ$99.33B+7.8%$16.09B16.2%$675.92B
ABBV$66.01B+10.7%$10.34B15.7%$519.48B
MRK$67.38B+4.9%$2.45B3.6%$364.98B
NVS$54.53B+8.4%$13.98B25.6%$311.52B
AZN$58.74B+8.6%$10.22B17.4%$289.61B
ABT$48.23B+10.0%$4.70B9.7%$191.31B
NVODKK 309.06B+6.4%DKK 102.43B33.1%$180.22B

OKUR FAQ

7 questions
  • What is OKUR revenue?
    OnKure Therapeutics Inc. (OKUR) reported $4.14M of revenue for the twelve months ended Sep 30, 2026. Revenue for fiscal 2025 was $3.44M.
  • Is OKUR profitable?
    No. OnKure Therapeutics Inc. reported a net loss of $61.85M for the twelve months ended Sep 30, 2026.
  • How much cash and debt does OKUR have?
    OnKure Therapeutics Inc. reported $151.44M in cash and cash equivalents on its most recent balance sheet in SEC filings.
  • What is OKUR free cash flow?
    OnKure Therapeutics Inc. generated -$47.94M of free cash flow for the twelve months ended Sep 30, 2026, which is operating cash flow of -$47.89M less capital expenditures.
  • What is OKUR earnings per share?
    Diluted earnings per share were -$2.76 for the twelve months ended Sep 30, 2026, from SEC filings, restated for any stock split those filings show.
  • When did OKUR last report financial results?
    The latest statements here come from OnKure Therapeutics Inc.'s 10-Q filed on Nov 4, 2026, covering the period ended Sep 30, 2026.
  • Where does this OKUR financial data come from?
    Quantisnow builds these statements from the structured XBRL data OnKure Therapeutics Inc. files with the SEC. It is provided for information only and is not investment advice.